Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.

European journal of medicinal chemistry - 5 Nov 2024

Pandey Divya, Chauhan Subhash C, Kashyap Vivek K, Roy Kuldeep K

Abstract excerpt

The Kirsten rat sarcoma viral (KRAS) oncogene is the most frequently mutated isoform of RAS, associated with 85 % of RAS-driven cancers. KRAS functions as a signaling hub, participating in various cellular signaling pathways and regulating a wide range of important activities, including cell proliferation, differentiation, growth, metabolism, and migration. Despite being the most frequently altered oncogenic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Molecular Structure

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Small Molecule Libraries

Share to Structure-Activity Relationship

Source

Identifiers

PMID: 39167893
DOI: 10.1016/j.ejmech.2024.116771

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.PMID 39167893Read ↗

Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design.Semantic proximity Read ↗

Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics.Semantic proximity Read ↗

Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.Semantic proximity Read ↗

From bench to bedside: current development and emerging trend of KRAS-targeted therapy.Semantic proximity Read ↗

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.Semantic proximity Read ↗

Annual review of KRAS inhibitors in 2022.Semantic proximity Read ↗

Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.Semantic proximity Read ↗

Targeting KRAS in cancer.Semantic proximity Read ↗

Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance.Semantic proximity Read ↗

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.Semantic proximity Read ↗

The path to the clinic: a comprehensive review on direct KRASG12C inhibitorsSemantic proximity Read ↗

Strategies for Targeting KRAS: A Challenging Drug Target.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.